Drug Trial Radar · NCT07737769
Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 26, 2026
Primary completion
Nov 2028
Study completion Nov 2029
Sponsor
- Lead sponsor
- University of Michigan Rogel Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, best dose and how well arsenic trioxide works to prevent relapse in patients undergoing allogenic stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Chemotherapy drugs, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic trioxide may be safe, tolerable and/or effective in preventing relapse in patients undergoing allogenic stem cell transplant for AML or MDS.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell TransplantationProcedure
Given IV
Arsenic TrioxideDrug
Given IV
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
BusulfanDrug
Given IV
FludarabineDrug
Given fludarabine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicitiesTime frame: From baseline to day 35 post hematopoietic stem cell transplant (HCT)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.